|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 38/16 | |
| A61K 38/17 | |||
| A61K 38/22 | |||
| A61K 48/00 | |||
| C12N 15/86 | |||
| C12N 15/867 | |||
| A61P 35/00 | |||
| C12N 9/78 |
| (11) | Patento numeris | 2547353 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11766479.7 |
| Europos patento paraiškos padavimo data | 2011-03-29 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-01-23 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2019-03-06 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2011/030402 |
| Data | 2011-03-29 |
| (87) | Numeris | WO 2011/126864 |
| Data | 2011-10-13 |
| (30) | Numeris | Data | Šalis |
| 318728 P | 2010-03-29 | US |
| (72) |
GRUBER, Harry, E., US
JOLLY, Douglas, J., US
PEREZ, Omar, US
OSTERTAG, Derek, G., US
ROBBINS, Joan, M., US
|
| (73) |
Tocagen Inc.,
3030 Bunker Hill Street Suite 230, San Diego, CA 92109,
US
|
| (54) | Medical use of a therapeutic combination comprising a thymosin-1-alpha polypeptide and a replication competent retroviral vector for the expression of cytosine deaminase. |
| Medical use of a therapeutic combination comprising a thymosin-1-alpha polypeptide and a replication competent retroviral vector for the expression of cytosine deaminase. |